ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc (ADIL)

1.035
0.035
( 3.50% )
Updated: 10:05:56

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.035
Bid
1.03
Ask
1.04
Volume
1,751,882
1.02 Day's Range 1.15
0.765 52 Week Range 8.875
Market Cap
Previous Close
1.00
Open
1.08
Last Trade
100
@
1.035
Last Trade Time
10:05:56
Financial Volume
$ 1,904,052
VWAP
1.0869
Average Volume (3m)
3,093,496
Shares Outstanding
4,233,308
Dividend Yield
-
PE Ratio
-0.93
Earnings Per Share (EPS)
-1.21
Revenue
-
Net Profit
-5.12M

About Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Adial Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ADIL. The last closing price for Adial Pharmaceuticals was $1. Over the last year, Adial Pharmaceuticals shares have traded in a share price range of $ 0.765 to $ 8.875.

Adial Pharmaceuticals currently has 4,233,308 shares outstanding. The market capitalization of Adial Pharmaceuticals is $4.23 million. Adial Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.93.

ADIL Latest News

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

GLEN ALLEN, Va., July 31, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (โ€œAdialโ€ or the โ€œCompanyโ€), a clinical-stage biopharmaceutical company focused on developing...

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

GLEN ALLEN, Va., July 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (โ€œAdialโ€ or the โ€œCompanyโ€), a clinical-stage biopharmaceutical company focused on developing...

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

GLEN ALLEN, Va., June 20, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (โ€œAdialโ€ or the โ€œCompanyโ€), a clinical-stage biopharmaceutical company focused on developing...

Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studiesand support ongoing partnership discussions Topline results expected in early Q4 2024 GLEN ALLEN, Va...

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

GLEN ALLEN, Va., May 29, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (โ€œAdialโ€ or the โ€œCompanyโ€), a clinical-stage biopharmaceutical company focused on developing...

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (โ€œAdialโ€ or the โ€œCompanyโ€), a clinical-stage biopharmaceutical company focused on developing...

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (โ€œAdialโ€ or the โ€œCompanyโ€), a clinical-stage biopharmaceutical company focused on developing...

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

GLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (โ€œAdialโ€ or the โ€œCompanyโ€), a clinical-stage biopharmaceutical company focused on developing...

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.095-8.407079646021.131.370.933911271711.14025775CS
4-0.015-1.428571428571.0530.933987521981.3033688CS
12-0.495-32.35294117651.5330.933930934961.30407202CS
26-0.145-12.28813559321.184.120.76546578991.99998486CS
52-5.99-85.26690391467.0258.8750.76523681632.06004701CS
156-59.465-98.289256198360.51270.76512057439.52267123CS
260-44.465-97.725274725345.51270.765101138324.26611532CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NCNCnoco noco Inc
$ 0.2986
(95.16%)
104.53M
NUZENuZee Inc
$ 6.2097
(67.83%)
22.52M
LSHLakeside Holding Ltd
$ 3.58
(51.05%)
16.98M
FAASDigiAsia Corporation
$ 2.69
(35.86%)
555.11k
POWLPowell Industries Inc
$ 180.79
(35.68%)
638.12k
FGENFibroGen Inc
$ 0.4936
(-52.08%)
6.27M
IMNNImunon Inc
$ 1.65
(-50.30%)
6.86M
PEPGPepGen Inc
$ 9.42
(-44.52%)
560.95k
DHDefinitive Healthcare Corporation
$ 3.38
(-41.11%)
1.11M
SYTASiyata Mobile Inc
$ 0.2698
(-31.00%)
2.73M
PRSTPresto Technologies Inc
$ 0.0419
(19.71%)
110.5M
NVDANVIDIA Corporation
$ 114.57
(10.45%)
110.03M
NCNCnoco noco Inc
$ 0.2986
(95.16%)
104.53M
FFIEFaraday Future Intelligent Electric Inc
$ 0.3588
(13.54%)
75.19M
MHUAMeihua International Medical Technologies Company Ltd
$ 1.1399
(10.67%)
52.19M

ADIL Discussion

View Posts
Awl416 Awl416 1 hour ago
Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044
๐Ÿ‘๏ธ0
FROZENFLAME FROZENFLAME 1 week ago
Looks like green very soon !
๐Ÿ‘๏ธ0
FROZENFLAME FROZENFLAME 1 week ago
Interesting !
๐Ÿ‘๏ธ0
glenn1919 glenn1919 1 week ago
ADIL............................https://stockcharts.com/h-sc/ui?s=ADIL&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
tw0122 tw0122 1 week ago
Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Source: GlobeNewswire Inc.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (โ€œAdialโ€ or the โ€œCompanyโ€), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the progression to the second cohort in the pharmacokinetics study of AD04, the Companyโ€™s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day), following the successful completion of the first cohort. Topline results from both cohorts are expected to be announced during the fourth quarter of 2024.
Cary Claiborne, President and Chief Executive Officer of Adial commented, โ€œWe are pleased with the progress of our pharmacokinetics study of AD04. The successful completion of the first cohort allows us to advance to the second cohort as planned, staying on track with our projected timeline. The results from both cohorts will offer invaluable insights that are critical for the design of our upcoming Phase 3 Clinical Trial. We anticipate engaging with the FDA following receipt of the topline data from this study and seek their feedback on the overall design of our Phase 3 program.โ€

The pharmacokinetics study was initiated in June 2024 and is expected to be completed during the fourth quarter of 2024. The single-center open-label relative bioavailability and dose proportionality study will enroll up to 30 healthy adult volunteers and compare the pharmacokinetic profile of AD04 when administered as an oral dose of 0.33 mg with or without food against a reference standard product. This study will provide valuable information on the pharmacokinetic properties of AD04.

๐Ÿ‘๏ธ0
Monksdream Monksdream 2 weeks ago
ADIL under $2
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 weeks ago
ADIL under $2
๐Ÿ‘๏ธ0
glenn1919 glenn1919 2 months ago
ADIL....................https://stockcharts.com/h-sc/ui?s=ADIL&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Monksdream Monksdream 3 months ago
ADIL under $1
๐Ÿ‘๏ธ0
Awl416 Awl416 3 months ago
What leaked?
๐Ÿ‘๏ธ0
44Skell 44Skell 3 months ago
Where to now ADIL?
๐Ÿ‘๏ธ0
Klinsmann Klinsmann 3 months ago
Sorry to say, I was deadly wrong on this one... But Iยดm holding and adding.
๐Ÿ‘๏ธ0
Klinsmann Klinsmann 3 months ago
Holding up very well. And flagging for the next uptick. Jep, itโ€˜s supposed to happenโ€ฆ
👍️ 1
44Skell 44Skell 3 months ago
Isnโ€™t this stock suppose to be ticking up
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 4 months ago
ADIL: Boy, am I eatin' 'CROW' on this one, or what!!! (Likely Close today at $5.00, just to humiliate me even more!!!)


"Heck, I trash a stock, & then it soars to the MOON!!! I HATE when this happens!!! NO RESPECT, at all!!!"
🤣 1
glenn1919 glenn1919 4 months ago
ADIL...............................https://stockcharts.com/h-sc/ui?s=ADIL&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Invest-in-America Invest-in-America 4 months ago
ADIL: This is what one gets behind 'investing' in a mere Ultra-Pre-Human-Trials, Petri Dish, Test Tude, Theoretical Journal Paper, and otherwise, 'THE-GREAT-ALCOHOL-ADDICTION-MAYBE-COULD-BE-MIGHT-BE-YEARS-FROM-NOW-CURE-OF-THE-WEEK', fluffy, Wall Street 'news' routine.
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 4 months ago
tHANKS adiL 1.82
๐Ÿ‘๏ธ0
Klinsmann Klinsmann 4 months ago
Congrats- chart looks primed for moreโ€ฆ
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 4 months ago
filled 1.97 on that dip
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 4 months ago
$ADIL 2.54 LET MORE GO, WHAT A GREAT STOCK TO TRADE

https://finviz.com/quote.ashx?t=ADIL&ty=c&ta=1&p=d

$adil lots of trade oppshttps://t.co/0eN6zQg6CR— THE FINAL COUNTDOWN (@READY_2_PROFIT) April 10, 2024
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 4 months ago
CONGRAT$
๐Ÿ‘๏ธ0
TheFinalCD TheFinalCD 4 months ago
nhod https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174209695
๐Ÿ‘๏ธ0
Klinsmann Klinsmann 4 months ago
Overdue- go time again!
๐Ÿ‘๏ธ0
Awl416 Awl416 4 months ago
What leaked?
๐Ÿ‘๏ธ0
Klinsmann Klinsmann 4 months ago
Added more shares - rumors about a big pharma deal hopefully get published soonโ€ฆ
๐Ÿ‘๏ธ0
Monksdream Monksdream 4 months ago
ADIL 10Q due 3/18
๐Ÿ‘๏ธ0
maent maent 5 months ago
I'm totally out. It was a nice bounce. We will see if it drops back into a buy zone. GL all.
๐Ÿ‘๏ธ0
Bill_ENG Bill_ENG 5 months ago
Except for the failed Phase III and then the company not doing anything except for a reverse split in two years.

They need to run more trials it will take 3 to 4 years to prove effectiveness and a higher probability it will fail those trials.

Having a patent on something that doesn't work is not worth much.

Jmho
๐Ÿ‘๏ธ0
glenn1919 glenn1919 5 months ago
ADIL................................................https://stockcharts.com/h-sc/ui?s=ADIL&p=W&b=5&g=0&id=p86431144783
๐Ÿ‘๏ธ0
Lottoplay Lottoplay 5 months ago
โ€œAD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesityโ€ my projected selling price just went higher! I didnโ€™t know it treated gambling and obesity in addition to alcoholism and opioid addiction! BOOM!!!
๐Ÿ‘๏ธ0
Lottoplay Lottoplay 5 months ago
BOOM! Posted yesterday! โ€œADIL this company has the potential to be worth #BILLIONS and at the same time help alcoholics and opioid addicts! Making money and helping humanity, who doesnโ€™t want to be a part of that!โ€
๐Ÿ‘๏ธ0
maent maent 5 months ago
I'm now looking for a nice bounce over $5
๐Ÿ‘๏ธ0
BurgerKing82 BurgerKing82 5 months ago
This one looks good
๐Ÿ‘๏ธ0
Lottoplay Lottoplay 5 months ago
$ADIL this company has the potential to be worth #BILLIONS and at the same time help alcoholics and opioid addicts! Making money and helping humanity, who doesnโ€™t want to be a part of that! 🚀
๐Ÿ‘๏ธ0
Awl416 Awl416 5 months ago
Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
๐Ÿ‘๏ธ0
maent maent 5 months ago
I'm looking for a nice bounce back over $1
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
ADIL new 52 week low
๐Ÿ‘๏ธ0
maent maent 5 months ago
My stop loss hit at 1.04
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
ADIL new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 5 months ago
ADIL new 52 week low
๐Ÿ‘๏ธ0
maent maent 5 months ago
Looks like a nice entry point here.
๐Ÿ‘๏ธ0
eb0783 eb0783 5 months ago
Cat got your tongue?
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
ADIL new 52 week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
ADIL new 52=week low
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
ADIL new 52 week low
🌈 1 🍆 1 👎️ 1 🤡 1 🩳 1
Monksdream Monksdream 6 months ago
ADIL new 52 week high
๐Ÿ‘๏ธ0
Monksdream Monksdream 6 months ago
ADIL new 52 week low
๐Ÿ‘๏ธ0
Muhbruh Muhbruh 7 months ago
$ADIL another small bio getting attention now pic.twitter.com/oCNyRr81Tj— STOCKS Gambino (@StocksGambino) December 29, 2023
๐Ÿ‘๏ธ0
Zorro Zorro 8 months ago
Volume picking up but also dropping in price. Looks like there is historic support in the 1.80 area.
๐Ÿ‘๏ธ0